

Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

Opicapone (Ongentys)

Notes:

- Quantity Limits: Yes

Non-Formulary **opicapone (Ongentys)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-Formulary **opicapone (Ongentys)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a neurologist
- Patient has a diagnosis of Parkinson's disease
- Patient is experiencing at least 2-hours "off" time per day despite maximally tolerated levodopa/carbidopa
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to:
 - Entacapone **AND**
 - An MAO-B inhibitor (selegiline, rasagiline) **OR** a dopamine agonist (ropinirole, pramipexole)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-Formulary **opicapone (Ongentys)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a diagnosis of Parkinson's disease
- Patient has failed an adequate trial of, or patient has an allergy or intolerance to:
 - Entacapone **AND**
 - An MAO-B inhibitor (selegiline, rasagiline) **OR** a dopamine agonist (ropinirole, pramipexole)

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-Formulary **opicapone (Ongentys)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

kp.org

Revised: 09/12/24
Effective: 11/21/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Clinical Oversight Review Board (CORB) Criteria for Prescribing/
Criteria-Based Consultation (CBC) Criteria for Coverage

Opicapone (Ongentys)

- Prescribed by a neurologist
- Patient has experienced a positive clinical response to treatment, as documented by neurologist

kp.org

Revised: 09/12/24
Effective: 11/21/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest